Mitochondrial Iron Overload-Mediated Inhibition of Nrf2-HO-1/GPX4 Assisted ALI-Induced Nephrotoxicity

Hui-Fang Deng, Lan-Xin Yue, Ning Ning Wang, Yong-Qiang Zhou, Wei Zhou, Xian Liu, Yu-Hao Ni, Cong-Shu Huang, Li-Zhen Qiu, Hong Liu, Hong-Ling Tan, Xiang-Lin Tang, Yu Guang Wang, Zeng-Chun Ma, Yue GaoFrontiers in Pharmacology 2021 · DOI

Abstract

Aristolactam I (ALI), a metabolite of aristolochic acid found in certain traditional medicines, is linked to aristolochic acid nephropathy (AAN). This study investigates the role of ferroptosis—an iron-dependent form of cell death—in ALI-induced kidney injury. Using HK-2 cells, researchers found that ALI triggers mitochondrial iron overload and suppresses the Nrf2-HO-1/GPX4 antioxidant pathway. These findings suggest that targeting mitochondrial iron and antioxidant defenses could provide a therapeutic strategy for preventing ALI-induced nephropathy.

Introduction

Aristolochic acid nephropathy (AAN) is a severe kidney condition caused by the ingestion of plants containing aristolochic acids. Aristolactam I (ALI) is a primary toxic metabolite of these acids. While previous research focused on apoptosis, this study explores ferroptosis, characterized by iron-dependent lipid peroxidation. The authors hypothesize that ALI-induced toxicity is driven by a failure in the cell's antioxidant systems coupled with an influx of iron into the mitochondria.

Methods

The study utilized human proximal tubular epithelial cells (HK-2) as a model. Key experimental techniques included:

  • Cell Viability Assays: Testing ALI's effect on cell survival and the rescue potential of various inhibitors (Ferrostatin-1 for ferroptosis, DFO for iron chelation).
  • Fluorescence Imaging: Measuring intracellular and mitochondrial iron levels (Mito-FerroGreen) and reactive oxygen species (MitoSOX).
  • Biochemical Analysis: Quantifying glutathione (GSH) levels and lipid peroxidation markers (4-HNE).
  • Protein Expression: Western blotting to assess the Nrf2-HO-1/GPX4 antioxidant axis.

Key Results

Dose-Dependent Cytotoxicity

ALI treatment resulted in a significant, dose-dependent decrease in HK-2 cell viability. The study identifies a clear reduction in cell survival as ALI concentration increases, establishing its potent nephrotoxicity.

Figure B: ALI inhibits HK-2 cell viability in a dose-dependent manner.

Iron Overload and Ferroptosis

A hallmark of ferroptosis is the accumulation of intracellular iron. The study observed a sharp increase in ferrous ion ($Fe^{2+}$) concentrations as ALI dosage increased, particularly at levels above 12.5 μM. This accumulation was specifically noted within the mitochondria, leading to the generation of reactive oxygen species.

Figure E: ALI treatment leads to a significant increase in intracellular ferrous ion concentration.

Furthermore, the iron chelator deferoxamine (DFO) and the ferroptosis inhibitor Ferrostatin-1 (Fer-1) significantly mitigated ALI-induced cell death, whereas inhibitors of apoptosis or necroptosis were less effective. This identifies ferroptosis as the primary driver of ALI nephrotoxicity.

Suppression of Antioxidant Defenses

ALI was found to dismantle the cell's primary defense against oxidative stress. It dose-dependently inhibited the expression of Nrf2 (the master regulator of the antioxidant response), HO-1 (a cytoprotective enzyme), and GPX4 (the essential enzyme for neutralizing lipid peroxides). The depletion of glutathione (GSH) further confirmed the collapse of the cellular antioxidant capacity, leaving membranes vulnerable to iron-induced lipid peroxidation.

Discussion

The researchers propose a mechanism where ALI induces mitochondrial iron overload, leading to the generation of mitochondrial reactive oxygen species (mtROS). This oxidative stress then inhibits the Nrf2-HO-1/GPX4 pathway, creating a lethal feedback loop that culminates in ferroptotic cell death. While these in vitro results provide a clear molecular pathway, further in vivo studies are necessary to confirm these mechanisms in complex biological systems. Nevertheless, the identification of the Nrf2-HO-1/GPX4 axis as a target offers a promising avenue for developing interventions against aristolochic acid-induced kidney damage.

Summary updated

Abstract

Aristolactam I (ALI) is an active component derived from some Traditional Chinese medicines (TCMs), and also the important metabolite of aristolochic acid. Long-term administration of medicine-containing ALI was reported to be related to aristolochic acid nephropathy (AAN), which was attributed to ALI-induced nephrotoxicity. However, the toxic mechanism of action involved is still unclear. Recently, pathogenic ferroptosis mediated lipid peroxidation was demonstrated to cause kidney injury. Therefore, this study explored the role of ferroptosis induced by mitochondrial iron overload in ALI-induced nephrotoxicity, aiming to identify the possible toxic mechanism of ALI-induced chronic nephropathy. Our results showed that ALI inhibited HK-2 cell activity in a dose-dependent manner and significantly suppressed glutathione (GSH) levels, accompanying by significant increases in intracellular 4-hydroxynonenal (4-HNE) and intracellular iron ions. Moreover, the ALI-mediated cytotoxicity could be reversed by deferoxamine mesylate (DFO). Compared with other inhibitors, Ferrostatin-1 (Fer-1), a ferroptosis inhibitor, obviously alleviated ALI-induced cytotoxicity. Furthermore, we have shown that ALI could remarkably increase the levels of superoxide anion and ferrous ions in mitochondria, and induce mitochondrial damage and condensed mitochondrial membrane density, the morphological characteristics of ferroptosis, all of which could be reversed by DFO. Interestingly, ALI dose-dependently inhibited these protein contents of nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase-1 (HO-1), and glutathione peroxidase 4 (GPX4), which could be partly rescued by Tin-protoporphyrin IX (SnPP) and mitoTEMPO co-treatment. In conclusion, our results demonstrated that mitochondrial iron overload-mediated antioxidant system inhibition would assist ALI-induced ferroptosis in renal tubular epithelial cells, and Nrf2-HO-1/GPX4 antioxidative system could be an important intervention target to prevent medicine containing ALI-induced nephropathy.
BibTeX
@inproceedings{deng2021mitochondrial,
  author = {Hui-Fang Deng and Lan-Xin Yue and Ning Ning Wang and Yong-Qiang Zhou and Wei Zhou and Xian Liu and Yu-Hao Ni and Cong-Shu Huang and Li-Zhen Qiu and Hong Liu and Hong-Ling Tan and Xiang-Lin Tang and Yu Guang Wang and Zeng-Chun Ma and Yue Gao},
  title = {{Mitochondrial Iron Overload-Mediated Inhibition of Nrf2-HO-1/GPX4 Assisted ALI-Induced Nephrotoxicity}},
  booktitle = {Frontiers in Pharmacology},
  year = {2021},
  doi = {10.3389/fphar.2020.624529},
}
Figure